Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) announced 20.7 month median overall survival (OS) from a prior single-arm Phase II trial evaluating bavituximab in combination with docetaxel in patients with locally advanced or metastatic breast cancer. In a separate published study included in the docetaxel package insert, median OS was 11.7 months for metastatic breast cancer patients treated with docetaxel alone.

Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the research and development of monoclonal antibodies for the treatment of cancer and viral infections.

To read more at : http://doubleinstocks.com/?p=18280